Oriana Ciani1, Daniele Grassi, Rosanna Tarricone. 1. Center for Research on Health and Social Care Management, Bocconi University, Via Roentgen, 1, 20136 Milan, Italy. oriana.ciani@unibocconi.it
Abstract
BACKGROUND: Urinary tract infection (UTI) is a leading cause of morbidity in the female population, with high levels of prevalence and recurrence within 6 months. OBJECTIVES: Our objective was to estimate annual costs and health resource utilization by women with UTIs, and the impact on quality of life (QoL) due to lower urinary tract symptoms (LUTS), vaginal pain and dyspareunia. The secondary objective was to estimate the cost per episode of cystitis in a subgroup of patients with recurrent UTIs. DESIGN AND PARTICIPANTS: We conducted a retrospective analysis of medical records of a cohort of 309 female patients with a history of UTI. Annual costs and costs per episode were estimated as composites of costs per diagnosis, costs per pharmacological therapy and costs per physician visit, according to the Italian National Health Service (NHS) perspective. RESULTS: The mean number of episodes of cystitis per patient was 4.5 (median [interquartile range, IQR] 3 [1-6]). The mean time from the onset of symptoms was 9 years (median [IQR] 7 [3-11]), excluding 13 % of values missing for this variable. Recurrent UTIs were diagnosed in 122 (39 %) patients. Overall, 243 (78 %) patients had an impaired sex life and 51 (17 %) had interrupted sex lives as a result of UTIs. Patients' median rates of discomfort due to LUTS or dyspareunia on a visual analogue scale (VAS) of 0-10 were 8 (IQR 7-10) and 8 (IQR 8-10), respectively. Mean annual direct cost per patient due to UTI was €229 (median [IQR] €107 [€53-241]), estimated mean direct cost per episode in patients with UTI was €236; whilst in women with recurrent UTI, the mean direct cost per episode was €142 (p < 0.0001). CONCLUSION: Annual mean costs and impact on QoL caused by UTIs are not negligible. Patients resign themselves to the relief of symptoms with recurring UTIs because improvement in health benefit is minimal. Persistence of the disease and the difference in mean costs per episode in patients with recurrent UTIs versus patients with a single episode UTI, which we have called "costs of resignation", suggest that appropriate early evaluation and effective treatment measures for the disease are still difficult in clinical practice.
BACKGROUND:Urinary tract infection (UTI) is a leading cause of morbidity in the female population, with high levels of prevalence and recurrence within 6 months. OBJECTIVES: Our objective was to estimate annual costs and health resource utilization by women with UTIs, and the impact on quality of life (QoL) due to lower urinary tract symptoms (LUTS), vaginal pain and dyspareunia. The secondary objective was to estimate the cost per episode of cystitis in a subgroup of patients with recurrent UTIs. DESIGN AND PARTICIPANTS: We conducted a retrospective analysis of medical records of a cohort of 309 female patients with a history of UTI. Annual costs and costs per episode were estimated as composites of costs per diagnosis, costs per pharmacological therapy and costs per physician visit, according to the Italian National Health Service (NHS) perspective. RESULTS: The mean number of episodes of cystitis per patient was 4.5 (median [interquartile range, IQR] 3 [1-6]). The mean time from the onset of symptoms was 9 years (median [IQR] 7 [3-11]), excluding 13 % of values missing for this variable. Recurrent UTIs were diagnosed in 122 (39 %) patients. Overall, 243 (78 %) patients had an impaired sex life and 51 (17 %) had interrupted sex lives as a result of UTIs. Patients' median rates of discomfort due to LUTS or dyspareunia on a visual analogue scale (VAS) of 0-10 were 8 (IQR 7-10) and 8 (IQR 8-10), respectively. Mean annual direct cost per patient due to UTI was €229 (median [IQR] €107 [€53-241]), estimated mean direct cost per episode in patients with UTI was €236; whilst in women with recurrent UTI, the mean direct cost per episode was €142 (p < 0.0001). CONCLUSION: Annual mean costs and impact on QoL caused by UTIs are not negligible. Patients resign themselves to the relief of symptoms with recurring UTIs because improvement in health benefit is minimal. Persistence of the disease and the difference in mean costs per episode in patients with recurrent UTIs versus patients with a single episode UTI, which we have called "costs of resignation", suggest that appropriate early evaluation and effective treatment measures for the disease are still difficult in clinical practice.
Authors: K G Naber; B Bergman; M C Bishop; T E Bjerklund-Johansen; H Botto; B Lobel; F Jinenez Cruz; F P Selvaggi Journal: Eur Urol Date: 2001-11 Impact factor: 20.096
Authors: Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper Journal: Clin Infect Dis Date: 2011-03-01 Impact factor: 9.079
Authors: R Ikäheimo; A Siitonen; T Heiskanen; U Kärkkäinen; P Kuosmanen; P Lipponen; P H Mäkelä Journal: Clin Infect Dis Date: 1996-01 Impact factor: 9.079
Authors: Stacy M Lenger; Megan S Bradley; Debbie A Thomas; Marnie H Bertolet; Jerry L Lowder; Siobhan Sutcliffe Journal: Am J Obstet Gynecol Date: 2020-06-01 Impact factor: 8.661
Authors: Stacy M Lenger; Christine M Chu; Chiara Ghetti; Michael J Durkin; Zoe Jennings; Siobhan Sutcliffe; Jerry L Lowder Journal: Female Pelvic Med Reconstr Surg Date: 2022-06-01 Impact factor: 1.913
Authors: Kimberley Chiu; Fan Zhang; Siobhan Sutcliffe; Indira U Mysorekar; Jerry L Lowder Journal: Female Pelvic Med Reconstr Surg Date: 2022-03-01 Impact factor: 2.091
Authors: Oriana Ciani; Erik Arendsen; Martin Romancik; Richard Lunik; Elisabetta Costantini; Manuel Di Biase; Giuseppe Morgia; Eugenia Fragalà; Tomaskin Roman; Marian Bernat; Giorgio Guazzoni; Rosanna Tarricone; Massimo Lazzeri Journal: BMJ Open Date: 2016-03-31 Impact factor: 2.692
Authors: M François; T Hanslik; B Dervaux; Y Le Strat; C Souty; S Vaux; S Maugat; C Rondet; M Sarazin; B Heym; B Coignard; L Rossignol Journal: BMC Health Serv Res Date: 2016-08-09 Impact factor: 2.655